Outlook Therapeutics Q1 2022 Earnings Report

Outlook Therapeutics reported financial results for the first quarter of fiscal year 2022 and provided a corporate update.

Key Takeaways

Outlook Therapeutics reported a net loss attributable to common stockholders of $14.5 million, or $0.08 per basic and diluted share, for the fiscal first quarter ended December 31, 2021. The company's cash and cash equivalents were $70.2 million at the end of the quarter.

Completed wet AMD clinical program for ONS-5010 with positive top-line data from NORSE TWO pivotal Phase 3 clinical trial.

Plans to submit a new BLA under the Public Health Service Act (PHSA) 351(a) regulatory pathway in the first quarter of calendar 2022.

Began commercial launch planning for ONS-5010, including partnerships for drug substance and product manufacturing.

Closed a $57.5 million gross proceeds equity offering in November 2021.